Life Sciences Gross to Net: Getting it Right

Pharmaceutical manufacturers have long had complex go-to-market models which have only become more complex in recent years due to regulatory changes and ever-evolving market strategies. This underscores the importance of gross-to-net (GTN) processes, which identify the true-net price, provide inputs to forecasts, and assist in the development of pricing strategies. Failure to develop accurate GTN models and calculations can lead to misstatements of net revenues that directly affects manufacturers’ bottom lines.  

This paper explores how manufacturers are able to improve and optimize their GTN processes. Refining operational processes, specifically in data analytic capabilities, will enhance the GTN model and equip manufacturers with what is needed to develop effective pricing strategies. 

KPMG offers a complete range of integrated growth and performance enhancement services to support clients throughout the GTN cycle.  Let us show you how.